TOYOBO (3101) FY2026 Q3 Earnings Report

Quick View

Executive Summary

The results showed a substantial increase in earnings despite lower revenue, with improved profitability being the key highlight. Revenue was limited to ¥3,075.2B (-2.1% YoY), while Operating Income increased significantly to ¥182.7B (+79.6%), and Ordinary Income rose to ¥158.4B (+186.2%). Net income attributable to owners of the parent for the quarter amounted to ¥78.3B, a substantial increase from ¥7.2B in the same period of the previous year. The primary drivers of the earnings increase were improvements in gross margin and the SG&A expense ratio resulting from a better product mix and fixed-cost absorption, rather than revenue growth driven by higher volumes.

Factors Affecting Results

【Revenue】Revenue was ¥3,075.2B, down 2.1% YoY. By segment, Films increased revenue to ¥1,300.5B (+4.1%), while Environment & Functional Materials at ¥778.8B (-6.7%), Functional Fibers & Trading at ¥662.2B (-7.1%), and Life Science at ¥248.1B (-3.6%) all reported lower revenue. The core Films business partially offset the company-wide revenue decline.

【Profit and Loss】Operating Income was ¥182.7B (+79.6%), and the Operating Income margin improved to 5.9% from approximately 3.2% in the same period of the previous year, an improvement of approximately 2.7pt. The gross profit margin was 24.9%, while the SG&A expense ratio was 19.0%, indicating progress in profitability improvement despite lower revenue. Ordinary Income was ¥158.4B (+186.2%), as the improvement at the operating level flowed through. However, extraordinary losses of ¥40.9B, including impairment losses of ¥2.5B and losses on disposal of fixed assets of ¥13.8B, put pressure on Profit Before Tax, which stood at ¥117.5B. Net income attributable to owners of the parent increased substantially to ¥78.3B from ¥7.2B in the same period of the previous year. Overall, the results represented higher earnings despite lower revenue.

Segment Analysis

The Films Business reported revenue of ¥1,300.5B (+4.1%), segment profit of ¥128.7B (+235.6%), and a profit margin of 9.9%, improving by approximately 6.8pt from 3.1% in the previous year. It became the core earnings source, accounting for 62.8% of total segment profit. Environment & Functional Materials reported revenue of ¥778.8B (-6.7%) and profit of ¥53.5B (-4.7%), maintaining a profit margin of 6.9%. Functional Fibers & Trading reported revenue of ¥662.2B (-7.1%), while profit improved from ¥0.6B to ¥5.8B. Real Estate reported revenue of ¥41.8B (+7.4%) and profit of ¥15.3B (+11.7%), maintaining a highly profitable margin of 36.6%. In contrast, Life Science reported revenue of ¥248.1B (-3.6%), and segment income/loss turned from a profit of ¥14.9B in the same period of the previous year to a loss of ¥2.8B, becoming a drag on company-wide profit. While the sharp recovery in Films drove overall profitability, the high concentration of profit contributions warrants attention.

Key Financial Indicators

【Profitability】The Operating Income margin of 5.9% improved from approximately 3.2% in the same period of the previous year. The gross profit margin was 24.9%, and the SG&A expense ratio was 19.0%. ROE was 4.0%, and the net profit margin was 2.5%; although profitability improved, capital efficiency remains at a low level.【Cash Quality】Cash and deposits were ¥245.8B, accounts receivable and notes receivable were ¥797.1B, and inventories were ¥677.4B. Operating receivables and inventories remain large, making the pace at which earnings improvement translates into cash generation an important point to monitor.【Investment Efficiency】Property, plant and equipment totaled ¥3,013.1B, accounting for 48.8% of total assets, reflecting a capital-intensive structure. The monetization of the investment pipeline, including construction in progress, will determine future capital efficiency.【Financial Soundness】The Equity Ratio was 39.1%, while net assets expanded to ¥2,409.5B from ¥2,320.4B in the previous year. The company carried long-term borrowings of ¥1,122.0B, bonds of ¥670.0B, and short-term borrowings of ¥504.6B. Although interest coverage remained high relative to interest payments of ¥21.2B, cash and deposits were below short-term borrowings, making short-term liquidity management an ongoing priority.

Cash Flow Analysis

Although the company did not disclose a cash flow statement, cash flow trends are analyzed based on movements in the balance sheet. Cash and deposits were ¥245.8B, down from ¥285.8B in the same period of the previous year, indicating that on-hand liquidity contracted despite substantial improvements in Operating Income and Ordinary Income. Accounts receivable and notes receivable were ¥797.1B, while inventories were ¥677.4B, both remaining at high levels. The long turnover days relative to revenue suggest that earnings improvement may not yet be sufficiently translating into cash generation. Short-term borrowings of ¥504.6B exceeded cash and deposits, and the issuance of ¥100.0B in commercial paper was also confirmed, indicating that short-term funding is primarily being financed through borrowings. Continued investment in property, plant and equipment and construction in progress may also be contributing to pressure on free cash flow.

Quality of Earnings

Ordinary Income of ¥158.4B was calculated by adding non-operating income of ¥22.9B and subtracting non-operating expenses of ¥47.3B, including interest payments of ¥21.2B, from Operating Income of ¥182.7B. This indicates a structure in which interest costs constrain the increase in earnings at the ordinary income level. In the transition to Profit Before Tax of ¥117.5B, extraordinary losses of ¥40.9B, including impairment losses of ¥2.5B and business restructuring expenses of ¥3.7B, were recorded, with temporary factors impeding the conversion into final profit. Comprehensive Income was ¥142.2B, and the portion attributable to owners of the parent was ¥117.8B, exceeding net income attributable to owners of the parent of ¥78.3B. This was supported by valuation-related increases, including foreign currency translation adjustments of ¥42.1B and a ¥3.6B valuation difference on available-for-sale securities. The divergence between Net Income and Comprehensive Income was primarily attributable to foreign currency translation gains and should be distinguished from changes in the underlying earning power of the business.

Earnings Forecast and Guidance

Progress against the full-year company forecast was 3,075.2B/4,300.0B for revenue, representing a progress rate of 71.5%; 182.7B/240.0B for Operating Income, representing a progress rate of 76.1%; and 158.4B/195.0B for Ordinary Income, representing a progress rate of 81.2%. Using the standard progress rate of 75% at the end of Q3 as a benchmark, revenue was slightly below the benchmark, while Operating Income and Ordinary Income exceeded it. This suggests that the company’s plan is premised more on profitability improvement than on revenue growth. The progress rate for net income attributable to owners of the parent was high at 92.1% (¥78.3B/¥85.0B), leaving only a limited amount of profit required in Q4. Nevertheless, the occurrence of extraordinary losses and the earnings trends of the Life Science Business remain potential sources of variation in the full-year outcome.

Shareholder Returns

The full-year dividend forecast is ¥40 per share, resulting in a Payout Ratio of approximately 41.5% based on the full-year EPS forecast of ¥96.36. The actual Q2 dividend was ¥0 per share, suggesting a policy of concentrating dividend payments at year-end. Based on 89,048,792 issued shares, using the effective share count after deducting 804 thousand treasury shares, the total annual dividend is estimated to be in the ¥3.5B range, which is a reasonable level relative to the full-year forecast net income of ¥85.0B. Net income attributable to owners of the parent for the nine months ended Q3 was ¥78.3B, reaching 92.1% of the full-year forecast, and the dividend funding source is expected to be secured if the plan is achieved.

Risk Factors

1. Concentration of earnings in the Films Business: Segment profit of ¥128.7B accounts for 62.8% of total segment profit. Fluctuations in demand, pricing, and utilization rates in this business could have a significant impact on company-wide Operating Income.

2. Deterioration in the profitability of the Life Science Business: Revenue was ¥248.1B (-3.6%), while segment income/loss turned from a profit of ¥14.9B in the same period of the previous year to a loss of ¥2.8B, representing a downside factor in the business portfolio.

3. Short-term liquidity and interest burden: Short-term borrowings of ¥504.6B exceeded cash and deposits of ¥245.8B. Interest payments of ¥21.2B are putting pressure on Ordinary Income, making it important to monitor interest-rate conditions and refinancing trends.

Industry Benchmark (For Reference; Company Research)

Industry Benchmark (manufacturing)

Profitability and Returns

Although improvement from the same period of the previous year was observed, both the Operating Income margin and net profit margin remained below the industry median.

Growth and Capital Efficiency

The revenue growth rate was near the lower bound of the industry median and interquartile range, indicating a notable revenue decline relative to industry peers.

※Source: Company research

Key Takeaways from the Results

1. The Operating Income margin improved to 5.9% from approximately 3.2% in the same period of the previous year, an improvement of approximately 2.7pt, demonstrating progress in profitability despite lower revenue. The improvement was centered on the rise in the Films Business profit margin from 3.1% to 9.9%, which is noteworthy as a qualitative change in the earnings structure.

2. The occurrence of extraordinary losses of ¥40.9B meant that the substantial increases in Operating Income and Ordinary Income were not fully reflected in Profit Before Tax and Net Income. It is important to note the difference between the improvement at the Ordinary Income level excluding temporary factors and the improvement at the final profit level.

3. Full-year progress rates were 76.1% for Operating Income, 81.2% for Ordinary Income, and 92.1% for net income attributable to owners of the parent, all exceeding the standard progress pace and confirming steady progress against the company plan. At the same time, the Life Science Business’s shift into the red indicates the absence of a growth driver capable of complementing the Films-led recovery.

Theoretical Share Price (Reference Value)

Sensitivity: ¥1,929–¥2,040 at ±1% for the cost of equity, and ¥1,973–¥1,990 at ±0.1 for ω.

Notes:

• Since progress of net income against the full-year forecast (92%) exceeds the standard level (75%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies progressing ahead of plan tend to outperform forecasts; the adjustment may be excessive for businesses with strong seasonality).
• Net income is substantially compressed relative to Operating Income due to tax burdens, acquisition-related expenses, and non-controlling interests, among other factors (Net Income ÷ Operating Income 35%). This figure reflects that compression at face value; if these factors are temporary, the underlying value may be higher.
• Since forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the end of the quarter are used (there is a timing difference relative to the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type; explicit 5-year fade) / Interest-rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q3 earnings showed a substantial operational recovery despite a 2.1% YoY decline in revenue to ¥307.5bn. Operating income increased 79.6% YoY to ¥18.3bn, lifting the operating margin to 5.9% from 3.2% in the prior-year period, a 270bp expansion. Gross profit rose 7.7% YoY to ¥76.6bn while SG&A expenses declined 4.3% to ¥58.3bn, demonstrating meaningful cost leverage. Ordinary income rose 186.2% to ¥15.8bn, although the improvement was moderated below the operating line by higher financing and other non-operating costs. Profit attributable to owners of the parent increased sharply to ¥7.8bn from ¥0.7bn a year earlier. Net margin remained modest at 2.5%, however, and the annualized ROE of 4.3% remains below a level that would indicate strong capital efficiency. Film was the clear earnings driver, with segment profit more than tripling as profitability recovered materially. The company-wide operating recovery was achieved even as most major industrial segments experienced lower revenue, indicating that pricing, product mix and cost control were more important than volume growth. Life Science moved into a segment loss, while Environment & Functional Materials saw a modest profit decline, limiting the breadth of the recovery. Extraordinary losses of ¥4.1bn reduced pre-tax income by 25.8% relative to ordinary income and constrained the translation of improved operating earnings into bottom-line profit. Interest expense increased to ¥2.1bn from ¥1.5bn, and the interest burden ratio of 0.643 means financing costs and other non-operating expenses remain material to shareholder returns. Liquidity ratios are sound on a conventional current-assets basis, with a 171.2% current ratio and a 127.1% quick ratio, but cash covers only 0.49x of short-term debt. Working-capital intensity is a central issue, reflected in the quality alerts for receivable days, inventory days and a 178-day cash conversion cycle. Management's full-year operating-income forecast of ¥24.0bn appears attainable based on Q3 progress of 76.1%, although achievement depends on preserving Film profitability and avoiding further losses or demand deterioration in other materials businesses. The full-year profit attributable to owners forecast of ¥8.5bn is 92.1% achieved at Q3, leaving limited room for further extraordinary losses. The expected ¥40 annual dividend implies a forecast payout ratio of approximately 41.5%, which appears supportable by forecast earnings but remains dependent on restoring cash conversion.

Profitability Analysis

The annualized DuPont ROE is 4.3%, comprising a 2.5% net profit margin, 0.665x annualized asset turnover and 2.56x financial leverage. The weak component is net margin rather than asset turnover: operating performance improved, but non-operating costs and extraordinary losses kept the profit attributable margin at only 2.5%. Financial leverage supports reported ROE but also increases sensitivity to financing costs, an important consideration given the 0.643 interest burden and ¥2.1bn of interest expense. The most significant YoY change was operating profitability: operating income rose ¥8.1bn while revenue fell ¥6.7bn. Gross margin expanded to 24.9% from 22.6%, a 230bp improvement, and operating margin expanded 270bp to 5.9%. SG&A declined by ¥2.6bn, or 4.3% YoY, against the revenue decline of 2.1%, providing operating leverage. The core business is Film, the largest contributor to segment profit at ¥12.9bn, equivalent to about 62.8% of aggregate segment profit before corporate-cost adjustments. Film external revenue rose 4.1% YoY to ¥130.0bn and segment profit rose 235.6% to ¥12.9bn; its segment margin increased to 9.9% from 3.0%. Environment & Functional Materials generated ¥5.4bn of segment profit on ¥77.9bn of revenue, or a 6.9% margin, but revenue declined 6.8% and profit declined 4.7%. Functional Fibers & Trading improved from a near-break-even profit of ¥0.1bn to ¥0.6bn, although revenue fell 7.1% to ¥66.2bn. Life Science revenue fell 3.6% to ¥24.8bn and the segment recorded a ¥0.3bn loss versus a ¥1.5bn profit a year earlier. Real Estate remained highly profitable, with segment profit of ¥1.5bn on ¥3.4bn of revenue, or a 45.3% margin, while profit rose 11.7%. Corporate and unallocated costs fell to ¥2.2bn from ¥2.6bn, further supporting consolidated operating-income growth. The operating-margin recovery is encouraging, but its durability requires Film's elevated profitability to persist and loss-making Life Science to stabilize.

Growth Assessment

Revenue contracted 2.1% YoY to ¥307.5bn, so the earnings recovery was margin-led rather than driven by top-line expansion. Film was the only major reportable operating segment with revenue growth, while the other materials-related segments experienced lower sales. This concentration makes consolidated growth sensitive to Film demand, mix and pricing. The full-year sales forecast of ¥430.0bn implies Q3 cumulative progress of 71.5%, modestly below the standard 75% seasonal progress rate. The full-year operating-income forecast of ¥24.0bn is 76.1% achieved, broadly consistent with the standard Q3 progress rate. Ordinary-income progress is stronger at 81.2% against the ¥19.5bn forecast, reflecting the substantial year-to-date earnings rebound. Profit attributable to owners is 92.1% achieved against the ¥8.5bn forecast, which provides a buffer only if extraordinary losses do not recur materially in Q4. The forecast implies FY2026 sales growth of 1.9% and operating-income growth of 44.1%, indicating that management expects a recovery to continue but at a slower profit-growth rate than the Q3 cumulative result. Construction in progress stood at ¥49.4bn, or 16.4% of PPE, indicating a meaningful investment pipeline that could support future capacity, modernization or product upgrades. At the same time, the high inventory and cash-conversion-cycle alerts indicate that demand recovery must translate into shipments and collections rather than additional balance-sheet accumulation. Profit growth quality would improve if the company can expand revenue outside Film, restore Life Science to profitability and maintain the gross-margin gains already realized.

Financial Health

Financial liquidity is adequate by conventional balance-sheet measures: the current ratio is 171.2%, the quick ratio is 127.1%, and working capital is ¥109.3bn. Current assets of ¥262.8bn exceed current liabilities of ¥153.5bn by a wide margin. However, the liquidity profile is less comfortable when assessed against near-term borrowings: cash and deposits of ¥24.6bn cover only 0.49x of short-term debt, triggering the liquidity-stress alert. Short-term loans total ¥50.5bn, with an additional ¥10.0bn each of current bonds and commercial paper, making refinancing access and operating cash generation important. Interest-bearing debt is ¥162.7bn, while long-term loans are ¥112.2bn and bonds payable are ¥67.0bn. The reported D/E ratio of 1.56x is below the 2.0x aggressive-leverage warning threshold but remains elevated relative to a conservative capital structure. Debt/capital is 40.3%, marginally above the 40% investment-grade benchmark, while the short-term debt ratio of 31.0% indicates a meaningful but not dominant short-term funding reliance. Interest coverage is 8.62x, above the 5x strong benchmark, but the interest burden alert is material because the ratio of pre-tax profit to EBIT is only 0.643. In practical terms, roughly 36% of EBIT is absorbed between net interest and other non-operating effects before tax. Total equity increased ¥8.9bn YoY to ¥240.9bn, and owners' equity increased to ¥203.6bn, supported by improved earnings and positive comprehensive income. The equity ratio was 33.0%, up from 31.6%, but the balance sheet remains capital-intensive, with PPE accounting for 48.8% of total assets. Net defined benefit liability of ¥13.3bn and provisions for directors' retirement benefits of ¥1.9bn are additional long-term obligations to monitor. No current-ratio or D/E threshold breach is indicated, but low cash relative to short-term debt and elevated financing sensitivity temper the otherwise adequate liquidity assessment.

Notable B/S Changes

Raw materials: +¥8.8bn (+27.6%) - inventory build increases exposure to input-cost movements and reinforces the need for working-capital normalization. Work in process: +¥2.8bn (+12.7%) - additional capital is tied up in production, increasing execution and demand-conversion risk. Accounts receivable: -¥12.8bn (-13.9%) - a constructive reduction, although the 71-day receivable-days alert indicates collections remain a priority. Accounts payable: -¥5.7bn (-11.7%) - lower supplier financing partly offsets the cash benefit from lower receivables. Commercial paper: +¥5.0bn (+100.0%) - increased short-term market funding heightens refinancing sensitivity. Property, plant and equipment: +¥4.8bn (+1.6%) - the capital base remains substantial at 48.8% of total assets. Construction in progress: -¥6.5bn (-11.7%) to ¥49.4bn - investment remains significant at 16.4% of PPE, requiring monitoring for project completion and return generation. Total equity: +¥8.9bn (+3.8%) - improved earnings and comprehensive income modestly strengthened capitalization.

Cash Flow Quality

The key cash-conversion risk is working-capital intensity. Quality alerts identify receivable days of 71 days, above the 60-day warning threshold, indicating slower customer collection than is desirable for a manufacturing business. Inventory days are also flagged at 158 days under one measure and 80 days under another measure; both alerts indicate inventory management requires attention, with the 158-day measure particularly elevated. The cash conversion cycle is flagged at 178 days, well above the 120-day warning threshold, tying up capital in receivables and inventories for a prolonged period. Accounts receivable were ¥79.7bn and electronically recorded monetary claims were ¥14.4bn at quarter-end. Inventories were reported at ¥67.7bn, while raw materials were ¥40.7bn and work in process was ¥24.8bn, highlighting the importance of conversion from production-stage inventory into cash sales. Finished-goods exposure is particularly relevant in a materials manufacturer because demand shortfalls, price declines or product-cycle changes can increase valuation and obsolescence risk. Trade payables were ¥42.7bn and electronically recorded obligations were ¥2.9bn, providing some supplier financing but not eliminating the long cash conversion burden. Receivables declined from ¥92.5bn in the prior-year period, which is constructive, but raw materials increased from ¥31.9bn and work in process increased from ¥22.0bn. Operating-income growth therefore needs to be accompanied by further working-capital release to strengthen cash earnings quality. Extraordinary losses of ¥4.1bn also reduce the cash-generative capacity available for debt service, investment and shareholder distributions. The reported financial information supports assessment of balance-sheet working-capital risks, while the earnings-to-cash conversion conclusion should be monitored through subsequent operating-cash-flow disclosure.

Dividend Sustainability

The company forecasts a full-year dividend of ¥40 per share. Based on forecast EPS of ¥96.36, the implied dividend payout ratio is approximately 41.5%, below the 60% sustainability benchmark. This payout level appears reasonable relative to forecast profit attributable to owners of ¥8.5bn. The Q2 dividend was ¥0, consistent with an annual-end distribution structure rather than an interim-payment approach. The principal constraint on dividend resilience is not the forecast payout ratio itself but balance-sheet cash conversion. Cash of ¥24.6bn is modest relative to short-term debt, and the 178-day cash conversion cycle could limit discretionary cash availability if inventory or receivables rise. The company also operates with ¥162.7bn of interest-bearing debt and a reported D/E ratio of 1.56x, making preservation of earnings and cash flow important. The FY2026 Q3 profit attributable to owners of ¥7.8bn already represents 92.1% of full-year guidance, supporting the stated dividend if Q4 results remain stable. Conversely, extraordinary losses totaling ¥4.1bn year to date illustrate that bottom-line earnings remain exposed to non-recurring charges. Dividend sustainability would be strengthened by continued Film profitability, Life Science recovery, inventory normalization and cash coverage of short-term debt improving above the current 0.49x.

Risk Assessment

Business risks include Film is the principal earnings driver: its ¥12.9bn segment profit accounts for about 62.8% of aggregate segment profit before corporate-cost adjustments, creating concentration risk if demand, pricing or product mix weakens., Life Science recorded a ¥0.3bn segment loss after a ¥1.5bn prior-year profit, indicating execution, demand or cost risk in a business expected to diversify the earnings base., Environment & Functional Materials revenue declined 6.8% YoY and segment profit declined 4.7%, indicating that the recovery is not yet broad-based across the portfolio., As a materials manufacturer, the company faces industry-specific exposure to raw-material and energy-cost volatility, supply-chain disruptions, customer production cycles, foreign-exchange movements and environmental regulation., High inventory days create risk of slower-moving stock, valuation pressure and future margin dilution should end-market demand weaken..

Financial risks include The interest burden ratio of 0.643 is high: approximately 36% of EBIT is consumed before tax through net interest and other non-operating effects, reducing the benefit of operating-profit recovery., Cash/short-term debt of 0.49x triggers a liquidity-stress alert; reliance on refinancing and working-capital monetization remains material., D/E of 1.56x is not at the aggressive-leverage warning level, but it is elevated and increases earnings sensitivity to interest rates and credit-market conditions., Debt/capital of 40.3% is marginally above the 40% investment-grade benchmark., Extraordinary losses of ¥4.1bn, including ¥0.2bn of impairment loss, reduced pre-tax income and demonstrate exposure to asset-related and restructuring charges..

Key concerns include Receivable days of 71, inventory-day alerts of 158 and 80, and a 178-day cash conversion cycle are the highest-priority operational-financial concern because they constrain liquidity and can weaken earnings-to-cash conversion., The earnings rebound is primarily margin-driven despite lower consolidated revenue, so sustainability depends on maintaining cost discipline and Film profitability rather than simply extrapolating year-to-date profit growth., The gap between ordinary income of ¥15.8bn and profit before tax of ¥11.7bn is ¥4.1bn, or 25.8% of ordinary income, reflecting the material effect of extraordinary losses., Construction in progress of ¥49.4bn, equal to 16.4% of PPE, represents a meaningful investment pipeline whose timing, cost control and return generation should be monitored..

Investment Implications

Key takeaways include Operating profit rose 79.6% YoY and operating margin expanded 270bp to 5.9%, reflecting a meaningful profitability recovery., Film is the core business and delivered the largest improvement, with segment profit rising to ¥12.9bn and margin reaching 9.9%., Revenue fell 2.1% YoY and several major segments contracted, indicating the recovery has not yet become broad-based., The annualized ROE of 4.3% and 2.5% net margin remain modest despite operational progress., Working-capital alerts and cash coverage of only 0.49x of short-term debt are key constraints on financial flexibility., FY2026 guidance appears operationally within reach at Q3, but net-income guidance has limited tolerance for additional extraordinary charges..

Metrics to watch include Film segment revenue, segment margin and profit sustainability, Life Science return to segment profitability, Operating margin relative to the Q3 cumulative 5.9%, Receivable days of 71 and the pace of collections, Inventory days, raw-material and work-in-process balances, and finished-goods turnover, Cash conversion cycle relative to the 178-day alert level, Cash/short-term debt coverage relative to 0.49x, Interest expense, interest burden and interest coverage, Extraordinary losses, impairment charges and restructuring costs, Completion, capital discipline and returns from the ¥49.4bn construction-in-progress balance.

Regarding relative positioning, The company currently presents as a capital-intensive diversified materials manufacturer in operational recovery rather than a high-return compounder. Its 5.9% operating margin and 4.3% annualized ROE remain below stronger profitability benchmarks, but Film's 9.9% segment margin demonstrates that targeted businesses can earn materially higher returns. Relative financial positioning is mixed: current and quick ratios are healthy and interest coverage is solid, while leverage, low cash coverage of short-term debt and unusually long working-capital conversion create a more constrained risk profile.